Glucagon Receptor Signaling and Lipid Metabolism

Research output: Contribution to journalJournal article

Standard

Glucagon Receptor Signaling and Lipid Metabolism. / Galsgaard, Katrine D; Pedersen, Jens; Knop, Filip K; Holst, Jens J; Wewer Albrechtsen, Nicolai J.

In: Frontiers in Physiology, Vol. 10, 413, 2019.

Research output: Contribution to journalJournal article

Harvard

Galsgaard, KD, Pedersen, J, Knop, FK, Holst, JJ & Wewer Albrechtsen, NJ 2019, 'Glucagon Receptor Signaling and Lipid Metabolism', Frontiers in Physiology, vol. 10, 413. https://doi.org/10.3389/fphys.2019.00413

APA

Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019). Glucagon Receptor Signaling and Lipid Metabolism. Frontiers in Physiology, 10, [413]. https://doi.org/10.3389/fphys.2019.00413

Vancouver

Galsgaard KD, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ. Glucagon Receptor Signaling and Lipid Metabolism. Frontiers in Physiology. 2019;10. 413. https://doi.org/10.3389/fphys.2019.00413

Author

Galsgaard, Katrine D ; Pedersen, Jens ; Knop, Filip K ; Holst, Jens J ; Wewer Albrechtsen, Nicolai J. / Glucagon Receptor Signaling and Lipid Metabolism. In: Frontiers in Physiology. 2019 ; Vol. 10.

Bibtex

@article{3f702a4ffc484b248139672f6485b7fd,
title = "Glucagon Receptor Signaling and Lipid Metabolism",
abstract = "Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyperglycemia. Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein. Conversely, in animal models, increased glucagon receptor signaling has been linked to improved lipid metabolism. Glucagon acts primarily on the liver and by regulating hepatic lipid metabolism glucagon may reduce hepatic lipid accumulation and decrease hepatic lipid secretion. Regarding whole-body lipid metabolism, it is controversial to what extent glucagon influences lipolysis in adipose tissue, particularly in humans. Glucagon receptor agonists combined with glucagon-like peptide 1 receptor agonists (dual agonists) improve dyslipidemia and reduce hepatic steatosis. Collectively, emerging data support an essential role of glucagon for lipid metabolism.",
author = "Galsgaard, {Katrine D} and Jens Pedersen and Knop, {Filip K} and Holst, {Jens J} and {Wewer Albrechtsen}, {Nicolai J}",
year = "2019",
doi = "10.3389/fphys.2019.00413",
language = "English",
volume = "10",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Glucagon Receptor Signaling and Lipid Metabolism

AU - Galsgaard, Katrine D

AU - Pedersen, Jens

AU - Knop, Filip K

AU - Holst, Jens J

AU - Wewer Albrechtsen, Nicolai J

PY - 2019

Y1 - 2019

N2 - Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyperglycemia. Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein. Conversely, in animal models, increased glucagon receptor signaling has been linked to improved lipid metabolism. Glucagon acts primarily on the liver and by regulating hepatic lipid metabolism glucagon may reduce hepatic lipid accumulation and decrease hepatic lipid secretion. Regarding whole-body lipid metabolism, it is controversial to what extent glucagon influences lipolysis in adipose tissue, particularly in humans. Glucagon receptor agonists combined with glucagon-like peptide 1 receptor agonists (dual agonists) improve dyslipidemia and reduce hepatic steatosis. Collectively, emerging data support an essential role of glucagon for lipid metabolism.

AB - Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyperglycemia. Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein. Conversely, in animal models, increased glucagon receptor signaling has been linked to improved lipid metabolism. Glucagon acts primarily on the liver and by regulating hepatic lipid metabolism glucagon may reduce hepatic lipid accumulation and decrease hepatic lipid secretion. Regarding whole-body lipid metabolism, it is controversial to what extent glucagon influences lipolysis in adipose tissue, particularly in humans. Glucagon receptor agonists combined with glucagon-like peptide 1 receptor agonists (dual agonists) improve dyslipidemia and reduce hepatic steatosis. Collectively, emerging data support an essential role of glucagon for lipid metabolism.

U2 - 10.3389/fphys.2019.00413

DO - 10.3389/fphys.2019.00413

M3 - Journal article

C2 - 31068828

VL - 10

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - 413

ER -

ID: 217697571